Cardiovascular
An early biomarker or protein-expression read touches at most the first two of five axes — and tells you almost nothing about the three that actually decide translation. Worse, the field's headline surrogate may not track the outcome at all.
Genetic Cardiomyopathy Precision Therapies
- DOSSIER59 pp · 17 figures. Gene addition rescues haploinsufficiency but cannot fix a dominant-negative poison protein (PLN R14del).
- WORKBOOK21 sheets. A flagship finding: PKP2 arrhythmia benefit is decoupled from biopsy protein magnitude — a direct challenge to the headline surrogate.
- AUDIT90 / 100, release-ready (grounded 18/20). Zero retractions across 120 sources.
- HYPOTHESES14 falsifiable, dated, re-validated against the newest readouts.
Exactly what's inside Genetic Cardiomyopathy Precision Therapies.
The full research-report table of contents and every one of the 21 tables in the evidence workbook — the real structure of what you license, not a teaser.
- Executive Summary
- Scope and Evidence Integrity Statement
- Decision Snapshot Overview
- Buyer Decision Cheat Sheet
- Source Quality Dashboard
- The Five Axis Translation Model
- Cross Gene Cross Mechanism Convergence Map
- Evidence Maturity Matrix and Modality Comparison
- Key Findings
- Quantitative Evidence
- Mechanistic Deep Dive By Gene
- Delivery Durability and Immunogenicity
- Natural History and Biomarkers
- Evidence Standards and Minimal Viable Trial Designs
- Non Obvious Early Stage Opportunities
- Testable Hypotheses
- Most Valuable Next Studies
- Regulatory and Evidence Standards Pathway
- Ethical Access and Societal Considerations
- Competitive Landscape Commercial and Payer Strategy
- Strategic Recommendations
- Limitations
- Final Judgment
- Expert Review and Validation Note
- Appendix Methodology Glossary and Verification Log
- References
Guide
A structured table within the evidence workbook.
In this dossier: GENETIC CARDIOMYOPATHY PRECISION THERAPIES — EVIDENCE WORKBOOK (buyer-auditable)
Claim Ledger
Every factual claim in the report, independently re-verified against its primary source, each carrying a support verdict and a recalibrated evidence grade.
In this dossier: 70 customer-facing claims with independent verdicts + recalibrated grades
Evidence Table
The full registry of cited sources — PMIDs, NCTs and DOIs — with metadata, resolved live against the primary record.
In this dossier: full source registry (71 rows; cited-only subset in sheet 4 / References)
Source-Support Verdicts
The verbatim source excerpt behind each claim, with an independent verdict on whether the source actually supports it.
In this dossier: INDEPENDENT SOURCE-SUPPORT VERDICTS — verbatim excerpts + divergence from prior agent
Source Quality
A reconciled view of source quality across the evidence base, with the grading rationale.
In this dossier: SOURCE QUALITY SUMMARY — reconciled counts + grade recalibration
Gene Scorecard
Programs or modalities scored on the framework's axes — a structured, side-by-side comparison (expert, ordinal, non-evidentiary).
In this dossier: GENE / TARGET SCORECARD — mechanism class, modality fit, programs, evidence tier, key gap
Program Tracker
A structured tracker of the programs, signals and evidence in this dimension of the analysis.
In this dossier: PROGRAM / ASSET TRACKER — every named asset (verified vs ClinicalTrials.gov + primary disclosures)
Modality Comparison
A structured table within the evidence workbook.
In this dossier: matched to mechanism class, with delivery / durability / liability
Five-Axis Scorecard
Programs or modalities scored on the framework's axes — a structured, side-by-side comparison (expert, ordinal, non-evidentiary).
In this dossier: AXIS SCORECARD — ordinal (0–4), FENCED non-evidentiary; basis per row
Trial Tracker
A structured tracker of the programs, signals and evidence in this dimension of the analysis.
In this dossier: TRIAL / REGISTRY TRACKER — every NCT opened (verified vs ClinicalTrials.gov v2)
Immunogenicity-Safety
A structured table within the evidence workbook.
In this dossier: IMMUNOGENICITY & SAFETY TRACKER — capsid, NAb gating, AE profile, deaths/holds, immunosuppression
Biomarker-Endpoint
How candidate biomarkers map to clinical endpoints — the bridge from a measurement to an outcome.
In this dossier: BIOMARKER–ENDPOINT MAP — surrogate vs hard outcome; analytical vs clinical validation
Regulatory-Designation
Regulatory designations and pathways relevant to each program — noting that a designation is never an approval.
In this dossier: REGULATORY & DESIGNATION TRACKER — a designation is a development tool, NOT evidence of benefit
CMC-Manufacturing
A structured table within the evidence workbook.
In this dossier: CMC / MANUFACTURING READINESS — capsid, scale, potency, comparability (limited public data; ASSUMED where noted)
Figure Source Map
The provenance of every figure — its underlying data and how it was produced.
In this dossier: id, number, family, engine, anchor section, caption
Figure Attempt Ledger
The provenance of every figure — its underlying data and how it was produced.
In this dossier: all RENDERED (none PENDING); rebuilds the source ledger's 14 PENDING
Hypotheses Ledger
The forward-looking, falsifiable hypotheses — each with a predicted readout and an explicit disconfirming test.
In this dossier: 14 falsifiable, current; currency check (KEEP/UPDATE/REPLACE/NEW)
Next Studies
The highest-leverage experiments to run next, prioritized — a ready-made research agenda.
In this dossier: MOST VALUABLE NEXT STUDIES — 8 de-risking studies (question · design · success/failure · cost · sources)
Verification-Search Log
A dated log of the verification searches run — the audit trail behind the evidence.
In this dossier: VERIFICATION & SEARCH LOG — independent re-assessment + latest-developments search
Excluded Claims
Every claim we considered and removed, with the reason — showing the work, including what didn't make the cut.
In this dossier: all 66 re-adjudicated (26 recovered / 40 remain excluded); counts reconcile 70+66=136
Salvage Ledger
Claims recovered from the excluded set after deeper verification.
In this dossier: 26 excluded claims recovered into the dossier (improve, do not restart)
Click any table to see what it is.
Different buyers live in different tabs.
Click a buyer to see exactly what they get.
Every claim resolves to a primary source.
This dossier ships with its independent diligence audit. Evidence is labelled Established / Inferred / Hypothesis. A surrogate is never equated with outcome; a designation is never an approval.
Zemi Research publishes independent, pre-packaged research reports delivered as digital downloads (PDF + spreadsheet). These are information products — not medical, clinical, investment, legal, or professional advice; not a consulting, advisory, or regulated service; and they create no professional-client relationship. Provided for general informational use by industry professionals.